Immunovant, Inc.
NASDAQ:IMVT
15.41 (USD) • At close June 2, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.231 | 1.324 | 1.232 | 0.998 | 0.021 | 0 | 0 |
| Gross Profit
| 0 | -0.231 | -1.324 | -1.232 | -0.998 | -0.021 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 360.917 | 225.428 | 160.257 | 101.808 | 68.604 | 47.927 | 25.733 | 135.263 |
| General & Administrative Expenses
| 77.235 | 57.281 | 48.019 | 54.225 | 39.513 | 18.151 | 2.692 | 1.477 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | -2.692 | 0 |
| SG&A
| 77.235 | 57.281 | 48.019 | 54.225 | 39.513 | 18.151 | 0 | 1.477 |
| Other Expenses
| 0 | 0 | -0.253 | -0.781 | 0.328 | 0.412 | 0 | 0 |
| Operating Expenses
| 438.152 | 282.709 | 208.276 | 156.033 | 108.117 | 66.078 | 0 | 136.74 |
| Operating Income
| -438.152 | -282.709 | -198.469 | -156.159 | -107.789 | -65.666 | -0 | -136.74 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 25.203 | 23.94 | -2.675 | -0.781 | 0.328 | -2.513 | 0 | 0 |
| Income Before Tax
| -412.949 | -258.769 | -210.951 | -156.814 | -107.789 | -66.291 | -0 | -136.74 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.891 | 0.567 | 0.009 | -0.084 | -0.358 | 0.097 | 0.019 | 0 |
| Net Income
| -413.84 | -259.336 | -210.96 | -156.73 | -107.431 | -66.388 | -0 | -136.74 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0 | -13.68 |
| EPS Diluted
| -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0 | -13.67 |
| EBITDA
| 0 | -269.978 | -209.627 | -155.582 | -106.791 | -65.645 | -28.415 | 0 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |